These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2118328)

  • 21. Clinical efficacy and tolerance of fleroxacin in patients with urethritis caused by Chlamydia trachomatis.
    Pust RA; Ackenheil-Köppe HR; Weidner W; Meier-Ewert H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():227-30. PubMed ID: 3144543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
    Heim-Duthoy K; Peltier G; Awni W
    Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ciprofloxacin increases serum levels of theophylline.
    Raoof S; Wollschlager C; Khan FA
    Am J Med; 1987 Apr; 82(4A):115-8. PubMed ID: 3578320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
    Wise R; Kirkpatrick B; Ashby J; Griggs DJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):161-3. PubMed ID: 3105446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of rifampin on fleroxacin pharmacokinetics.
    Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man.
    Wijnands GJ; Cornel JH; Martea M; Vree TB
    Chest; 1990 Dec; 98(6):1440-4. PubMed ID: 2245687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fleroxacin clinical pharmacokinetics.
    Stuck AE; Kim DK; Frey FJ
    Clin Pharmacokinet; 1992 Feb; 22(2):116-31. PubMed ID: 1551289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
    Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
    Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between theophylline and enoxacin.
    Takagi K; Hasegawa T; Yamaki K; Suzuki R; Watanabe T; Satake T
    Int J Clin Pharmacol Ther Toxicol; 1988 Jun; 26(6):288-92. PubMed ID: 3165968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects.
    Gregoire SL; Grasela TH; Freer JP; Tack KJ; Schentag JJ
    Antimicrob Agents Chemother; 1987 Mar; 31(3):375-8. PubMed ID: 3472488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
    Sorgel F; Metz R; Naber K; Seelmann R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
    Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection.
    Heizmann P; Dell D; Eggers H; Gora R
    J Chromatogr; 1990 Apr; 527(1):91-101. PubMed ID: 2114419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofloxacin-induced theophylline toxicity: a population-based study.
    Antoniou T; Gomes T; Mamdani MM; Juurlink DN
    Eur J Clin Pharmacol; 2011 May; 67(5):521-6. PubMed ID: 21234553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.